Breaking News
January 17, 2019 - Educational videos in clinical settings increase HPV vaccination rates among adolescents
January 17, 2019 - Better understanding of aggressive brain tumour
January 17, 2019 - Why is life expectancy in the U.S. going down? A Q&A
January 17, 2019 - The Electronics Industry Sees Money In Your Health
January 17, 2019 - Hypertension drug may improve effectiveness of ovarian cancer treatment
January 17, 2019 - Scientists reveal key mechanism in worms that controls cell’s response to stress
January 17, 2019 - How Patch Clamp Technology Can Benefit Ion Channel Research
January 16, 2019 - Researchers cultivate organoids that perfectly mimic blood vessels
January 16, 2019 - Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis
January 16, 2019 - Unraveling the genetic causes of skin cancer
January 16, 2019 - Higher percentages of saturated fat in low-carb diets may not harm cholesterol levels, new analysis suggests
January 16, 2019 - Using bottled or tap water impacts health benefits of green tea
January 16, 2019 - Best trained alert dogs have potential to improve Type 1 diabetes patients’ quality of life
January 16, 2019 - States with lower incidence of melanoma have higher mortality rates
January 16, 2019 - Pollution on the London Underground found to be dangerously high
January 16, 2019 - Breast cancer cells in mice coaxed to turn into harmless fat cells
January 16, 2019 - Study connects the genetic background of autistic spectrum disorders with stem cell dysfunction
January 16, 2019 - When activated, ‘social’ brain circuits inhibit feeding behavior in mice | News Center
January 16, 2019 - How Exercise May Help Keep Our Memory Sharp
January 16, 2019 - Researchers identify a key regulator that stops excessive inflammation
January 16, 2019 - TGF-beta signaling pathway in uterine cells protects against cancer
January 16, 2019 - MD Anderson Cancer Center collaborates with Dragonfly for new immunotherapy drug clinical trials
January 16, 2019 - Drug Repurposing May Provide More Psychiatric Tx Options
January 16, 2019 - A new brain imaging study challenges the dominant theoretical model of autism spectrum disorders
January 16, 2019 - GoFundMe CEO: ‘Gigantic Gaps’ In Health System Showing Up In Crowdfunding
January 16, 2019 - Induced neuronal cells derived from fibroblasts are similar to neurons in the brain
January 16, 2019 - New study finds link between childhood abuse and suicide in later life
January 16, 2019 - Lifestyle and health factors that are good for the heart can also prevent diabetes
January 16, 2019 - Scientists take another step in understanding bacteria that cause Salmonella epidemic
January 16, 2019 - Look to Your Aunts, Uncles and Parents for Clues to Your Longevity
January 16, 2019 - Study finds ADHD drugs are unlikely to cause cardiac damage in children who take them
January 16, 2019 - Call The Midwife! (If The Doctor Doesn’t Object)
January 16, 2019 - Changes in hippocampal structural connectivity differentiate responders of electroconvulsive therapy
January 16, 2019 - Study sheds light on the deadly venom of Mojave rattlesnakes
January 16, 2019 - University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure
January 16, 2019 - Sugar-based stent makes precarious sewing process easier
January 16, 2019 - FDA-approved drug hampers cancer metastasis in animal model, shows study
January 16, 2019 - Low-level cannabis use can change the adolescent brain
January 16, 2019 - MTC in Rouen acquires Robocath’s R-One robot for future healthcare practitioner training
January 16, 2019 - OSSIO granted FDA 510(k) market clearance for OSSIOfiber Bone Pin Family
January 16, 2019 - Childhood body composition may play a role in future respiratory health
January 16, 2019 - Outdated commissioning methods are failing mental health services in the UK, reveals report
January 16, 2019 - Unconventional immune cells trigger disturbed cytokine production in human spondyloarthritis
January 16, 2019 - Patients Turn To GoFundMe When Money And Hope Run Out
January 16, 2019 - Researchers develop novel viral identification method
January 16, 2019 - Study proposes improvements in pharmacological study of cognitive function enhancers in schizophrenia
January 16, 2019 - Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis
January 16, 2019 - Differences in geographic origin of genes may affect mitochondrial function
January 16, 2019 - Study analyzes vaccine-preventable infections in children who receive solid organ transplants
January 16, 2019 - MiRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
January 16, 2019 - Scientists uncover why knee joint injury leads to osteoarthritis
January 16, 2019 - Salk team uses new model to study health effects of AMP-activated protein kinase
January 16, 2019 - Research reveals novel approach to suppressing chemotherapy-induced tumor growth
January 16, 2019 - Researchers reveal how fasting leads to better overall health
January 16, 2019 - Deprivation and neglect in early childhood have impact on cognitive functioning in adolescence, shows study
January 16, 2019 - Training Students to use Imaging Techniques: NMR and EPR
January 16, 2019 - Nerve transfer surgery restores arm movement in children with acute flaccid myelitis
January 16, 2019 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
January 16, 2019 - DNA vaccine reduces both toxic proteins linked to Alzheimer’s
January 16, 2019 - Even in the U.S., poor women often can't afford tampons, pads
January 16, 2019 - One time use of Marijuana could affect teen brains finds study
January 16, 2019 - Persistent Opioid Use High in Head, Neck Cancer Patients
January 16, 2019 - Questions to ask your doctor about post pregnancy care: MedlinePlus Medical Encyclopedia
January 16, 2019 - Neurons with good housekeeping are protected from Alzheimer’s
January 16, 2019 - Is mindfulness worthy of all the hype?
January 16, 2019 - Physical Activity, Any Type or Amount, Cuts Health Risk from Sitting
January 16, 2019 - New understanding in the evolution of human feet
January 15, 2019 - AHA: New Cholesterol Guidelines Put Ethnicity in the Spotlight
January 15, 2019 - Different brain areas linked to smoking and drinking
January 15, 2019 - Henry Marsh shares insights into neurosurgery and more at Dean’s Lecture Series
January 15, 2019 - Want to Live Longer? For Just 30 Minutes a Day, Do Anything Else But Sit
January 15, 2019 - The Current issue of “The view from here” is concerned with Targets
January 15, 2019 - Plain packaging sparked tobacco price rises, new study finds
January 15, 2019 - Sedentary lifestyles can be unhealthy, physical activity can lower risk
January 15, 2019 - Gut microbiome may help prevent development of cow’s milk allergy
January 15, 2019 - Lesbian, gay and bisexual individuals more likely to suffer severe substance use disorders
January 15, 2019 - New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder
January 15, 2019 - Levels of inflammatory marker (CRP) linked to housing type and tenure
January 15, 2019 - Three gifts I’m glad I gave myself in 2018
January 15, 2019 - Columbia’s Pediatrics Department Names New Vice Chairs, Expands Leadership
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

image_pdfDownload PDFimage_print

DUBLIN and SAN FRANCISCO October 16, 2018 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to five years.

“A large and diverse population of women already use Liletta as a safe, long-acting and reversible contraceptive option. This approval means that Liletta is now indicated for up to 5 years of use. To date, no hormonal IUD has been studied across more women in a single Phase 3 clinical trial conducted in the U.S.,” said Jessica Grossman, M.D., CEO of Medicines360. “In partnership with Allergan, we remain steadfast in our mission to help women access available birth control methods that are appropriate for them, regardless of their income.”

The FDA approval was based on a review of additional efficacy and safety data from the largest ongoing intrauterine system (IUS), otherwise known as intrauterine device (IUD), Phase 3 clinical trial in the U.S., ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS), with 1,751 U.S. women receiving Liletta. Liletta proved to be more than 99 percent effective in preventing pregnancy for up to 5 years in a broad range of women. Liletta is effective regardless of age, race, body mass index (BMI) or parity (whether or not the woman had given birth to at least one child).

“I hear from women every day that they want contraceptive options that are proven and provide them with flexibility in preventing pregnancy. Unfortunately, this isn’t always a reality,” said Thomas Kimble, M.D., associate dean, assistant professor of obstetrics and gynecology, Eastern Virginia Medical School and principal investigator in the pivotal ACCESS IUS study. “I can confidently recommend Liletta as a rigorously tested choice for patients who want long-term reversible birth control. The fact that it is now indicated for up to five years, instead of four, offers my patients the flexibility of use for either long- or short-term contraception.”

Liletta is a hormone-releasing system placed in a woman’s uterus to prevent pregnancy for up to five years. The system should be replaced after five years if continued use is desired. Medicines360 received initial approval of Liletta in February 2015. Since then, Medicines360 and Allergan have continued to invest in the product, which has led to the introduction of the single-handed inserter and, now, the extended duration of use for up to 5 years.

Liletta is commercially available in the U.S., and through Medicines360’s unique mission-driven model, Liletta is available at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.

“In our view, this is a landmark approval because it gives women, regardless of income, insurance status or geography, access to an effective and long-term form of hormonal contraception,” said David Nicholson, Ph.D., Allergan’s chief research and development officer. “We are pleased to strengthen our portfolio of contraceptive options and to continue delivering on our mission of helping women access a method that may be suited for them.”

About Liletta

Indication

Liletta (levonorgestrel-releasing intrauterine system) 52 mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 5 years.

About Medicines360

Medicines360, located in San Francisco, California, is a nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

About Allergan Women’s Healthcare

Allergan is a leader in women’s healthcare that is dedicated to developing and commercializing best-in-class pharmaceuticals to improve the health and wellness of women. Allergan takes a holistic and a best-in-class approach to women’s healthcare as it prioritizes educational partnerships with OB/GYNs and advocacy groups. The mission of Allergan Women’s HealthCare extends beyond its pharmaceutical products to ensure that all women can make informed decisions about their health and have access to high-quality medications. Allergan is committed to investing in programs that support the education and well-being of all women.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, debt reduction, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan’s Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

Source: Medicines360

Posted: October 2018

Related Articles:

Liletta (levonorgestrel) FDA Approval History

Tagged with:

About author

Related Articles